Vimta Labs Limited has informed the Exchange about Investor Presentation
Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F: +91 40 2726 3657
Vimta
Driven by Quality. Inspired by Science.
VLL SE 043 2023-24 Date: 28.07.2023
Listing Centre B S E Limited P J Towers, Dalal Street Mumbai: 400001 Scrip Code No.524394
Dear Sirs,
Asst Vice President National Stock Exchange of India Limited “Exchange Plaza”, Bandra Kurla Complex, Bandra (E Mumbai 400051 Trading Symbol: VIMTALABS
Reg:
Investor Presentation -QI results — FY 2023-24
to provisions of Regulation 30 of the SEBI
Pursuant (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) we are attaching herewith the Investor Presentation.
Further, pursuant to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., https://vimta.comlinvestor-nresentation/
This is for your information and necessary records.
Yours faith fi.illy,
for VIMTA LABS LIMITED
Sujani Vasireddi Company Secretary
Attachments: as above.
Life Sciences Campus, #5, MN Science & Technology Park, Genome Valley, Sharnirpet, Hyderabad -500 101, Telangana, India T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com CIN: L24110TG1990PLC011977
Vimta Labs Limited Investor Presentation Q1FY24
1
Disclaimer
The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.
This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.
No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.
2
Contents
Q1FY24 Earnings
Company Overview
Industry Landscape
Our Competitive Advantage
Way Forward
1
2
3
4
5
3
Q1FY24 Earnings
▪ Q1FY24 Highlights ▪ Key Metrics: Q1FY24 ▪ Profit & Loss Statement ▪ Financial Track Record ▪ Shareholding Pattern
01
4
Q1FY24 Highlights
Earnings Highlights
➢ Total Income for Q1FY24 were at Rs. 841 Mn
➢ EBITDA for Q1FY24 was Rs. 252 Mn; EBITDA margin remained steady at 30.0%
➢ Q1FY24 PAT was at Rs. 122 Mn; PAT margin for the quarter was at 14.5%
➢ Basic EPS was at Rs. 5.5 in Q1FY24 against Rs. 5.4 in Q1FY23
➢ Total Debt as of 30th June stood at Rs. 137 Mn down from Rs. 150 Mn as of 31st March 2023
➢ Cash and Cash equivalents were at Rs. 285 Mn as of 30th June 2023
➢ Q1FY24 Capex was at Rs 218 Mn
➢ Debt to Equity ratio was 0.05x
5
Key Metrics: Q1FY24
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
31.0%
30.1%
30.0%
800
825
841
248
248
252
15.4%
15.0%
PAT
PAT Margin
14.5%
120
127
122
16%
15%
15%
15%
15%
15%
14%
14%
14%
5
0
150
125
100
5.4
5.7
5.5
Q1FY23 Q4FY23 Q1FY24
Q1FY23 Q4FY23 Q1FY24
Q1FY23 Q4FY23 Q1FY24
Q1FY23 Q4FY23 Q1FY24
6
Profit & Loss Statement
Particulars (₹ Mn)
Revenue from Operations
Other Income
Total Income
Material and Testing Costs
Cost of lab setup
Changes in inventories of work-in-progress
Employee benefits expense
Other expenses
Total Expenses
EBIDTA (including Other income)
EBIDTA (%)
Finance costs
Depreciation expense
Exceptional Items
Profit before tax
PBT (%)
Tax
Profit for the year
PAT (%)
Basic EPS (INR)
Diluted EPS (INR)
Q1 FY24
Q1 FY23
Q4 FY23
835
6
841
204
2
0
247
136
588
252
791
9
800
190
3
0
227
132
552
248
818
7
825
188
1
1
220
167
576
248
30.0%
31.0%
30.1%
4
85
0
163
19.4%
41
122
14.5%
5.5
5.4
9
73
0
166
20.7%
46
120
15.0%
5.4
5.3
2
80
0
166
20.1%
39
127
15.4%
5.7
5.6
7
Financial Track Record
TOTAL INCOME (₹ Mn)
PROFITABILITY (₹ Mn)
EBITDA & EBITDA Margin
18%
25%
29%
31%
PAT & PAT Margin
15%
15%
1,837
2,115
2,797
3,216
20.5% CAGR
330
538
817
984
44.0% CAGR
4%
68
10%
214
413
482
92.1% CAGR
FY20
FY21
FY22
FY23
FY20
FY21
FY22
FY23
FY20
FY21
FY22
FY23
Total Revenue
EBIDTA
EBIDTA Margin
PAT
PAT Margin
BALANCE SHEET RATIOS
RoE (%)
RoCE (%)
Debt to Equity
Total Capex
4%
11%
18%
17%
15%
18%
25%
22%
0.16
0.16
0.08
0.05
166
357
450
492
FY20
FY21
FY22
FY23
FY20
FY21
FY22
FY23
FY20
FY21
FY22
FY23
FY20
FY21
FY22
FY23
8
Shareholding Pattern
Vimta Labs Shareholding as on 30th June 2023
Share Information (as on 30th June 2023)
NSE Ticker
BSE Ticker
Market Cap (INR Cr)
% free-float
Others 57.9%
Promoters 37.2%
Free-float market cap (INR Cr)
Total Debt (INR Mn)
Cash & Cash Equivalents (INR Mn)
VIMTALABS
524394
905
62.8%
568
137
285
Shares Outstanding
2,21,38,549
DII 2.1%
FII 2.7%
3M ADTV (Shares)*
3M ADTV (INR Cr)*
Industry
*Source: NSE & BSE
60,893
2.38
TIC
9
Company Overview
▪ Vimta Labs at a Glance ▪ Our Journey ▪ Services ▪ Geographical Presence ▪ Management ▪ Accreditation
02
10
Vimta Labs at a Glance
Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing.
39+ Years
Of experience in CRTO industry
400,000+
Sq.ft. of Ultra modern lab space
3,216
FY23 Total Revenue (In ₹ Mn)
Our Belief & Commitment
1,400+
75+
Dedicated Multi Disciplinary Team
Successful Regulatory Audits
19
Regional & Satellite labs across India
#1
In India: ➢ Pharma Analytical & Preclinical
Services
➢ Food Testing Services
984
FY23 EBIDTA (In ₹ Mn)
482
FY23 PAT (In ₹ Mn)
30.6%
EBIDTA MARGIN
15.0%
PAT MARGIN
14.9% YoY
20.3% YoY
16.6% YoY
11
Our Journey
Infrastructure
People
Investment
Capabilities
Revenues
`
`
2023
400,000+ ft2
1400+
492 M
2015
400,000+ ft2
1000+
580 M
2006
200,000+ ft2
600+
992 M
1992
50,000+ ft2
150+
85 M
Pharma & Biopharma: Discovery & development services; Food; Environment; Clinical Diagnostics; Electronics
Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment
Clinical Research; Environment; Analytical – Food & Pharma
Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research
3,216 M
1,073 M
542 M
16 M
1984
500 ft2
6
200,000
Minerals & ores; Metals; Rice bran oil testing
156,000
• •
Investment & Revenues in INR Investments depicted may have spread across more than the denoted year
12
Our Offerings (1/3)
Drug discovery and development support to Lifesciences Industry
Offerings
Industry
Accreditations & Regulatory Approvals
Food & Agriculture Services
Electronics & Electricals Testing
Clinical Diagnostics
Environment Testing & Consultancy
Pharma Analytical
Clinical Research
Preclinical Support
Pharmaceuticals
Pharmaceuticals
DCGI, USFDA, WHO, NPRA, UK MHRA and other European countries
Services
➢ Leader in India for a wide range of
➢ One of India’s most reputed and
analytical services for the pharmaceutical, biopharmaceutical and animal health industries.
➢ E&L studies ➢ Stability testing ➢ Method development ➢ Validations ➢ Genotoxic impurities ➢ Elemental analysis ➢ In vitro studies
➢ Physical
characterization ➢ Dissolution testing ➢ Microbiology ➢ Immunogenicity ➢ Characterization ➢ Bioassays
reliable CROs
➢ Experience of over 2,000 clinical
studies
➢ Impressive track record of
successful global regulatory audits from national and international regulatory authorities.
Pharmaceuticals, Biotech, Medical device, Agrochemicals
Good Laboratory Practices (GLP) - certified by NGCMA, and AAALAC accredited
➢ General and Genetic toxicology ➢ Safety pharmacology ➢ Development and Reproductive
Toxicology (DART) studies
➢ Immunotoxicology ➢ Comprehensive pharmacological and
drug metabolism and pharmacokinetic studies
➢ Wide gamut of Toxicology services also support agrochemical and medical device industries
13
Our Offerings (2/3)
Drug discovery and development support to Lifesciences Industry
Offerings
No. of Laboratories
Accreditations & Regulatory Approvals
Services
Food & Agriculture Services
Electronics & Electricals Testing
Clinical Diagnostics
Environment Testing & Consultancy
Food Testing
8
Electronics & Electricals Testing
1
FSSAI, NABL, BIS, APEDA, EIC, Spices Board
ISO 17025 accredited by NABL and approved by TEC
➢ VIMTA is a ‘National Referral Lab’ and a preferred
➢ Newly launched EMI / EMC services cater to IT,
laboratory partner for many MNCs, and also relied on by Government institutes for projects of national importance
automotive, aviation & defence, medical devices, telecom, home appliance / consumer electronics and allied industries
➢ Routine as well as specialized testing services for food and agriculture products to assist with R&D, regulatory compliance, trade and internal quality requirements
➢ Support new product development, and offer
multifarious analytical services for: ➢ The feed that sustains animal life ➢ Crops yielded by various soils ➢ All varieties of food and food products for consumption/export ➢ Milk, water and beverages ➢ Nutraceuticals
➢ Services provided are EMI / EMC TESTING, Radiated, Conducted, Environmental testing, Mechanical & electrical safety testing, Performance testing, Product certification
➢ The non EMI / EMC services are rendered through our wholly owned subsidiary, Emtac Laboratories Pvt. Ltd
14
Our Offerings (3/3)
Drug discovery and development support to Lifesciences Industry
Food & Agriculture Services
Electronics & Electricals Testing
Clinical Diagnostics
Environment Testing & Consultancy
Offerings
Clinical Diagnostics
Environment Testing & Consultancy
No. of Laboratories
2 (regional reference laboratories); 6 (branch laboratories)
NA
Accreditations & Regulatory Approvals
Services
ISO 15189 by NABL, CAP
MoEF, ISO 17025 by NABL, QCI/NABET, OSHAS 45000
➢ Strong brand equity and a pan India presence offering
➢ Environment Impact Assessments and Environment
both routine and specialized diagnostic services
➢ The hallmarks of our clinical diagnostics services are stringent quality systems, latest technologies and committed customer care ➢ Clinical diagnostics range:
➢ Biochemistry ➢ Haematology ➢ Molecular biology ➢ Microbiology ➢ Histopathology / Cytopathology ➢ Serology ➢ Cytogenetics
Testing since inception. Provide our services to various industries such as power, infrastructure, steel, cement, oil & gas, mining, pharmaceutical, food, chemical etc.
➢ Our Services:
➢ Testing of water, waste water,
air, soil, noise
➢ Post-project monitoring,
environment compliance studies ➢ EIA & social impact assessments ➢ Deep-ocean studies, marine
ecological studies
➢ Forestry and ecological studies ➢ Rejuvenation & clean-up
consultancy
➢ Ground water studies & contamination studies
➢ Site due diligence, remediation
strategies
➢ Social sustainability, climate change and environmental education projects ➢ Mining plan preparation ➢ EHS audits ➢ Work space monitoring etc. ➢ Green Audit
15
Geographical Presence
Headquartered in Hyderabad, VIMTA has 19 laboratories across India, with a total laboratory space of over 400,000 sq. ft.
Hyderabad (Headquarters)
Food
Clinical Diagnostics
Pharma
Electronics & Electrical
Environment
Food
Ahmedabad
Noida
Mumbai (NFL)
Pune
Bengaluru
Visakhapatnam
Nellore
Environment
Clinical Diagnostics
Coimbatore
Noida
Kolkata
Chennai
Delhi
Varanasi
Kolkata
Bhubaneswar
Visakhapatnam
Vijayawada
Tirupati
16
Key Management Team
S P Vasireddi Executive Chairman
Harita Vasireddi Managing Director
Sreenivas Neerukonda Executive Director
Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.
Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.
Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.
Her Core competencies include management & driving organizational adaptabilty and development, quality management systems, and risk management.
She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India
Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal oriented performance.
He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.
Key Management Team (Cont’d)
Harriman Vungal Executive Director - Operations
Suresh Kumar President
Narahari Naidu D.R. Chief Financial Officer
Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.
He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.
He holds D. Tech in Electronics from Toronto, Canada.
Suresh have more than two decades of experience in Testing, Inspection, Certification and Contract Research Organization with diversified products and industries.
He was with TUV SUD South Asia as Chief Operating Officer and Member of Board of Management before Joining VIMTA
He holds B.Sc (Tech) from ICT Mumbai and B.Sc (Polymer Chemistry) from Kerala university .
Narahari has close to 15 years of experience in diversified industries.
His core competencies include Financial Planning, Corporate Strategy, Fund raising, Banking & Treasury, Taxation, Investor Relations, Enterprise Risk Management, Compliance & Governance, Financial Reporting & Audit, Procurement Strategies.
He is a Chartered Accountant (CA) and a Company Secretary (CS).
18
Industry Landscape
▪ Market Opportunity ▪ Factors Driving Industry Growth
03
19
Markets Opportunity
Preclinical
Food Testing
Clinical Testing
Environment Testing
Electronics Testing
Pharmaceutical & Biopharmaceuticals
957.6
405.5
l
a b o G
l
76.6
127.3
19.5
40.5
76.2
124.7
11.1
20.2
6.8
13.4
2020 | 2028 CAGR: 11.3%
2023 | 2028 CAGR: 10.7%
2022 | 2032 CAGR: 7.5%
2022 | 2028 CAGR: 8.5%
2022 | 2030 CAGR: 7.8%
2021 | 2031 CAGR: 7.1%
) n b D S U (
i
n a d n
I
130.0
42.0
43.6
14.5
0.5
1.0
0.6
0.9
0.2
0.4
0.05
0.1
2021 | 2030
CAGR: 13.4%
2021 | 2030
CAGR: 7.5%
2022 | 2027
CAGR: 9.3%
2022 | 2032
CAGR: 11.6%
2021 | 2026
CAGR: 9.9%
2021 | 2028
CAGR: 8.6%
20
Factors Driving Industry Growth
Drug Discovery & Development
Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry
Specialized knowledge, skills and testing tools that CROs can provide
Food Testing
Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third- party inspection & testing
Electrical & Electronics Testing
Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives
Green push by Government for electrical vehicles
Environment Testing
Diagnostics
Increase in regulations to address the growing concerns of air, water and soil contamination
Health risks from communicable diseases, life style diseases, growing population and urbanization is driving the demand for precise diagnostic testing
Growing demand in wellness segment
21
Our Competitive Advantage
▪ Our Position in the CRTO Landscape ▪ Our Strength
04
22
Our Position in the CRTO Landscape
1
2
Pharma Analytical & Preclinical
5
Food Testing
#1 in India
#1 in India
Customers – 90% of India top 20
Customers – 70% of India top 10
30% revenues from overseas
Clinical Research
6
Environment
Among the most reputed CROs in India
Among top 5 in India
80% of revenues from overseas
Customers – PSUs, large corporations across industries
3
Clinical Diagnostics
7
Electronics & Electricals
Among leading labs in TS, AP, UP states
Start-up
23
Our Strengths
QUALITY Long & successful regulatory track record – cGMP, GLP, GCP
CUSTOMER CENTRICITY Long term partnerships with customers
INFRASTRUCTURE Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium
KNOWLEDGE
Multi-disciplinary, knowledgeable, skilled and trained manpower
TECHNOLOGY Wide range of current technologies with expandable capacities
24
Way Forward
▪ Our Key Growth Drivers & Strategies
05
25
Our Key Growth Drivers & Strategies
Favourable markets
Core business strategies
Core operational strategies
Best practices
✓ Growth momentum
✓ Capacity expansions
✓ Operational excellence
in markets
✓ Growing demand for safe & quality - drugs, food, diagnostics, electronics & clean environment
✓ Service innovations
✓ Hiring right talent
✓ Penetration into new
✓ Quality & compliance
markets
✓ Customer partnerships
culture
✓ Cutting edge technologies
✓ Good corporate governance
✓ Risk management
✓ Listening to customers’
needs
✓ Continuous learning
We aspire to reach revenues of >Rs.500 cr by 2025/2026
26
Thank You
July 2023
VIMTA LABS LIMITED
INVESTOR RELATIONS AT
Registered Office Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051
NSE: VIMTALABS, BSE: 524394 ISIN: INE579C01029 Website: www.Vimta.com
Vimta Labs Ltd. Narahai Naidu Dodda, CFO Narahai.Dodda@vimta.com
Rahul Thakur Rahul.Thakur@in.ey.com
Advait Bhadekar Advait.Bhadekar@in.ey.com
Copyright ©2023 Vimta Labs Limited
27